How do life sciences companies validate computerised systems in a GMP-compliant manner under GAMP 5 and EU GMP Annex 11?

Computer system validation is at its core a question of sequence, not of test volume. The EU GMP Guide Annex 11 and FDA 21 CFR Part 11 do not require maximum effort, but an effort that matches the risk of the system. That is why the GAMP 5 classification at the outset determines the whole project: a standard system essentially needs a supplier assessment and a PQ under real conditions, while a configured or bespoke system needs the full chain of URS, functional specification, traceability matrix, IQ, OQ and PQ. Skip this classification and you validate non-critical systems too deeply and GxP-critical ones too shallowly - and it is exactly this imbalance that an inspector finds first.

The second bottleneck comes after release. A validation report proves the state as at a cut-off date, not for the system's lifetime. Change control and periodic review keep the validated state in force: every update and every upgrade needs an impact assessment that defines the revalidation scope before it goes live. In parallel, data integrity must take hold technically in line with the ALCOA principles - an enabled, tamper-proof audit trail and role-based access control under Annex 11 and 21 CFR Part 11, not just as SOP text. Companies that plan for these two strands, lifecycle and data integrity, from the start shift the effort to where corrections are cheap, rather than into the inspection, where they become expensive.